CDKN2A and cancer: The reasons may be that management by genotyping alone is based solely on risk of cervical precancer or cancer without knowledge about what’s occurring within the cells [33]; it’s likely to miss the diagnosis for women who have infected certain genotype associated with a lower risk but that is already transforming into a cancerous disease; remarkably, p16 immunostaining is an indicator of malignant transformation of HPV infection and provides genotype agnostic risk information.